M J Mauro

Summary

Affiliation: Oregon Health and Science University
Country: USA

Publications

  1. ncbi Management of drug toxicities in chronic myeloid leukaemia
    Michael J Mauro
    Knight Cancer Institute, Center for Hematologic Malignancies, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, UHN 73C, Portland, OR 97239, USA
    Best Pract Res Clin Haematol 22:409-29. 2009
  2. ncbi Baseline disease risk and response to therapy in chronic myeloid leukemia: necessary predictive tools then and now
    Michael J Mauro
    Center for Hematologic Malignancies, Oregon Health and Science University, Portland, OR, USA
    Haematologica 90:291B. 2005
  3. ncbi Stem cell transplantation in patients with chronic myelogenous leukemia: when should it be used?
    Michael J Mauro
    Center for Hematologic Malignancies, Oregon Cancer Institute, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, UHN73C, Portland, OR 97239, USA
    Mayo Clin Proc 81:404-16. 2006
  4. ncbi Mutational analysis and overcoming imatinib resistance in chronic myeloid leukemia with novel tyrosine kinase inhibitors
    Michael J Mauro
    Center for Hematologic Malignancies, Oregon Health and Science University, Portland, OR 97239, USA
    Curr Treat Options Oncol 8:287-95. 2007
  5. ncbi Tailoring tyrosine kinase inhibitor therapy in chronic myeloid leukemia
    Michael J Mauro
    Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon 97239, USA
    Cancer Control 16:108-21. 2009
  6. ncbi Appropriate sequencing of tyrosine kinase inhibitors in chronic myelogenous leukemia: when to change? A perspective in 2009
    Michael J Mauro
    Center for Hematologic Malignancies, OHSU Knight Cancer Institute, Oregon Health and Science University, Portland, USA
    Curr Opin Hematol 16:135-9. 2009
  7. ncbi Response dynamics in chronic-phase chronic myeloid leukemia
    Michael J Mauro
    Center for Hematologic Malignancies, Oregon Cancer Institute Oregon Health and Science University, Portland, OR 97239, USA
    Clin Lymphoma Myeloma 9:217-22. 2009
  8. ncbi STI571: targeting BCR-ABL as therapy for CML
    M J Mauro
    Leukemia Program, Division of Hematology and Medical Oncology, Oregon Health Sciences University, 3181 Sam Jackson Park Road, Portland, OR 97201, USA
    Oncologist 6:233-8. 2001
  9. ncbi STI571: a gene product-targeted therapy for leukemia
    M J Mauro
    Leukemia Program, Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health Sciences University, OP28, 3181 SW Sam Jackson Park Road, Portland, OR 97201, USA
    Curr Oncol Rep 3:223-7. 2001
  10. ncbi ST1571, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia: validating the promise of molecularly targeted therapy
    M J Mauro
    Leukemia Program, Oregon Health Sciences University, Portland 97201, USA
    Cancer Chemother Pharmacol 48:S77-8. 2001

Collaborators

Detail Information

Publications25

  1. ncbi Management of drug toxicities in chronic myeloid leukaemia
    Michael J Mauro
    Knight Cancer Institute, Center for Hematologic Malignancies, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, UHN 73C, Portland, OR 97239, USA
    Best Pract Res Clin Haematol 22:409-29. 2009
    ..This article reviews the toxicities related to the currently available ABL inhibitors - their basis, relevance and management...
  2. ncbi Baseline disease risk and response to therapy in chronic myeloid leukemia: necessary predictive tools then and now
    Michael J Mauro
    Center for Hematologic Malignancies, Oregon Health and Science University, Portland, OR, USA
    Haematologica 90:291B. 2005
  3. ncbi Stem cell transplantation in patients with chronic myelogenous leukemia: when should it be used?
    Michael J Mauro
    Center for Hematologic Malignancies, Oregon Cancer Institute, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, UHN73C, Portland, OR 97239, USA
    Mayo Clin Proc 81:404-16. 2006
    ..This review summarizes the state of transplant and nontransplant therapy for CML and discusses the decision making for patients with an aim to optimize the use of our best therapies for CML in an era of uncertainty...
  4. ncbi Mutational analysis and overcoming imatinib resistance in chronic myeloid leukemia with novel tyrosine kinase inhibitors
    Michael J Mauro
    Center for Hematologic Malignancies, Oregon Health and Science University, Portland, OR 97239, USA
    Curr Treat Options Oncol 8:287-95. 2007
  5. ncbi Tailoring tyrosine kinase inhibitor therapy in chronic myeloid leukemia
    Michael J Mauro
    Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon 97239, USA
    Cancer Control 16:108-21. 2009
    ..Dasatinib and nilotinib are both active in chronic- and accelerated-phase CML, including patients with imatinib-resistant or intolerant disease...
  6. ncbi Appropriate sequencing of tyrosine kinase inhibitors in chronic myelogenous leukemia: when to change? A perspective in 2009
    Michael J Mauro
    Center for Hematologic Malignancies, OHSU Knight Cancer Institute, Oregon Health and Science University, Portland, USA
    Curr Opin Hematol 16:135-9. 2009
    ..Decision-making regarding key questions of initial therapy choice, role of allografting, and changes in therapy remains a fluid discussion; this review aims to give a current perspective...
  7. ncbi Response dynamics in chronic-phase chronic myeloid leukemia
    Michael J Mauro
    Center for Hematologic Malignancies, Oregon Cancer Institute Oregon Health and Science University, Portland, OR 97239, USA
    Clin Lymphoma Myeloma 9:217-22. 2009
    ..Longerterm follow-up data will be required to confirm CCyR as a surrogate marker for survival in imatinib-resistant patients treated with the secondgeneration tyrosine kinase inhibitors, dasatinib and nilotinib...
  8. ncbi STI571: targeting BCR-ABL as therapy for CML
    M J Mauro
    Leukemia Program, Division of Hematology and Medical Oncology, Oregon Health Sciences University, 3181 Sam Jackson Park Road, Portland, OR 97201, USA
    Oncologist 6:233-8. 2001
    ..Integration of STI571 into CML treatment algorithms will require long-term follow-up data from the ongoing phase II and III clinical studies...
  9. ncbi STI571: a gene product-targeted therapy for leukemia
    M J Mauro
    Leukemia Program, Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health Sciences University, OP28, 3181 SW Sam Jackson Park Road, Portland, OR 97201, USA
    Curr Oncol Rep 3:223-7. 2001
    ..Through rational drug development, STI571, a bcr-abl tyrosine kinase inhibitor, has emerged as a paradigm for gene product-targeted therapy, offering new hope for expanded treatment options for patients with CML...
  10. ncbi ST1571, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia: validating the promise of molecularly targeted therapy
    M J Mauro
    Leukemia Program, Oregon Health Sciences University, Portland 97201, USA
    Cancer Chemother Pharmacol 48:S77-8. 2001
    ..The results of clinical studies have demonstrated the potential of molecularly targeted therapies, and ST1571 is emerging as a new therapeutic agent for CML...
  11. ncbi Chronic myelogenous leukemia
    M J Mauro
    Leukemia Program, Oregon Health Sciences University, Portland, Oregon, USA
    Curr Opin Oncol 13:3-7. 2001
    ..Through rational drug development, STI571, a bcr-abl tyrosine kinase inhibitor, has emerged as targeted therapy that offers new hope for expanded treatment options for patients with CML...
  12. ncbi Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate
    K M Gatter
    Division of Hematology and Ocology, Department of Medicine, Oregon Health and Science University, Portland 97201, USA
    Leukemia 17:481-7. 2003
    ..The presence of clonal abnormalities in Ph-negative cells of imatinib-treated CML patients with MCR and CHR highlights the importance of routine metaphase cytogenetic testing and long-term follow-up of all imatinib-treated patients...
  13. ncbi Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate
    Michael E O'Dwyer
    Hematology Department, University College Hospital, Newcastle Road, Galway, Ireland
    Blood 103:451-5. 2004
    ....
  14. ncbi STI571: a paradigm of new agents for cancer therapeutics
    Michael J Mauro
    Leukemia Program, Division of Hematology and Medical Oncology, Oregon Health Sciences University, 3181 SW Sam Jackson Park Rd, Portland, OR 97201, USA
    J Clin Oncol 20:325-34. 2002
    ..Lastly, the potential use of STI571 in other malignancies and the translation of this paradigm to other malignancies are explored...
  15. ncbi Recent advancements in the treatment of chronic myelogenous leukemia
    Michael E O'Dwyer
    Leukemia Center, Oregon Cancer Institute, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, Oregon 97201, USA
    Annu Rev Med 53:369-81. 2002
    ..Through rational drug development, STI571, a Bcr-Abl tyrosine kinase inhibitor, has emerged as a paradigm for gene product targeted therapy, offering new hope for expanded treatment options for patients with CML...
  16. ncbi Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience
    Rita M Braziel
    Dept of Pathology, Oregon Health Sciences University, Portland, OR 97201, USA
    Blood 100:435-41. 2002
    ..Several patients acquired additional clonal cytogenetic abnormalities during therapy, a finding with significant implications for prognosis and laboratory monitoring in imatinib mesylate-treated CML patients...
  17. ncbi An intron-derived insertion/truncation mutation in the BCR-ABL kinase domain in chronic myeloid leukemia patients undergoing kinase inhibitor therapy
    Jennifer Laudadio
    Department of Pathology, Oregon Health and Science University, Portland, OR, USA
    J Mol Diagn 10:177-80. 2008
    ..These findings demonstrate that kinase domain insertions are an alternative (and not entirely uncommon) mutational mechanism in CML patients undergoing kinase inhibitor therapy...
  18. ncbi The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML
    Michael E O'Dwyer
    Leukemia Center, Oregon Health and Science University Cancer Institute, Portland, USA
    Blood 100:1628-33. 2002
    ..Once patients have other signs of acceleration, clonal evolution predicts lower response rates and a shorter time to treatment failure...
  19. ncbi A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response
    Richard D Press
    Department of Pathology, Center for Hematologic Malignancies, Cancer Institute, and Howard Hughes Medical Institute, Oregon Health and Science University, Portland, Oregon 97201, USA
    Clin Cancer Res 13:6136-43. 2007
    ..Although CCR is usually durable, a minority of patients relapse. Biomarkers capable of predicting those CCR patients with a higher risk of relapse would improve therapeutic management...
  20. ncbi BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML
    Richard D Press
    Department of Pathology, Oregon Health and Science University, Portland, OR 97201, USA
    Blood 107:4250-6. 2006
    ..1; 95% CI, 3.1-22; P < .001). The achievement of either a 2-log molecular response at the time of CCR or a 3-log response anytime thereafter is a significant and independent prognostic marker of subsequent progression-free survival...
  21. ncbi Chronic myeloid leukemia in 2006: a perspective
    Michael J Mauro
    Haematologica 91:152. 2006
  22. ncbi Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatment
    Ayalew Tefferi
    Department of Internal Medicine and Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    Mayo Clin Proc 80:390-402. 2005
    ..These issues are discussed within the context of clinical practice...
  23. ncbi STI571 as a targeted therapy for CML
    Michael J Mauro
    Leukemia Center, Oregon Health and Science University Cancer Institute, Portland, Oregon, USA
    Cancer Invest 21:429-38. 2003
    ..Thus, STI571 has emerged as a paradigm for gene product targeted therapy, offering expanded treatment options for patients with CML...
  24. ncbi Transplantation for chronic myelogenous leukemia: yes, no, maybe so. . . An Oregon perspective
    Richard T Maziarz
    Bone Marrow Transplantation Program/Leukemia Center, Center for Hematologic Malignancies, Oregon Cancer Institute, Oregon Health and Science University, Portland, OR 97239, USA
    Bone Marrow Transplant 32:459-69. 2003
    ..Optimal decision making regarding the use of these divergent therapies has not been defined. This paper reviews critical data relevant to these treatment options and provides an approach to current management of the CML patient...
  25. ncbi Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission
    Michael J Mauro
    Center for Hematologic Malignancies, Oregon Cancer Institute, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, UHN73C, Portland, OR 97239, USA
    Leuk Res 28:S71-3. 2004
    ....